Wall Street brokerages expect Medpace Holdings Inc (NASDAQ:MEDP) to report $0.63 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Medpace’s earnings, with the highest EPS estimate coming in at $0.65 and the lowest estimate coming in at $0.59. Medpace posted earnings per share of $0.40 in the same quarter last year, which suggests a positive year-over-year growth rate of 57.5%. The firm is expected to report its next earnings results on Monday, October 29th.

According to Zacks, analysts expect that Medpace will report full-year earnings of $2.44 per share for the current financial year, with EPS estimates ranging from $2.36 to $2.48. For the next year, analysts expect that the firm will post earnings of $2.85 per share, with EPS estimates ranging from $2.74 to $2.93. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow Medpace.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Tuesday, July 31st. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.19. Medpace had a net margin of 10.44% and a return on equity of 14.22%. The firm had revenue of $117.80 million for the quarter, compared to analysts’ expectations of $104.97 million. During the same quarter last year, the company earned $0.38 EPS. The firm’s revenue for the quarter was up 24.5% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the stock. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research note on Friday, August 10th. William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 31st. BidaskClub cut shares of Medpace from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Tuesday, July 3rd. Finally, Credit Suisse Group lifted their price target on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research note on Tuesday, July 31st. Six equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $43.83.

Medpace stock traded up $0.42 during trading on Friday, reaching $62.74. The company had a trading volume of 2,724 shares, compared to its average volume of 989,568. Medpace has a 1-year low of $30.62 and a 1-year high of $63.99. The stock has a market capitalization of $2.22 billion, a P/E ratio of 40.97, a P/E/G ratio of 1.60 and a beta of 1.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.68 and a current ratio of 0.68.

In other news, major shareholder Medpace Limited Partnership sold 5,224,997 shares of Medpace stock in a transaction on Monday, August 27th. The stock was sold at an average price of $54.75, for a total transaction of $286,068,585.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO August J. Troendle sold 731,460 shares of Medpace stock in a transaction on Monday, August 6th. The stock was sold at an average price of $59.26, for a total value of $43,346,319.60. Following the transaction, the chief executive officer now owns 849,621 shares in the company, valued at approximately $50,348,540.46. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,510,659 shares of company stock worth $633,131,950. Insiders own 29.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Laurion Capital Management LP purchased a new stake in Medpace in the 2nd quarter valued at about $29,230,000. BlackRock Inc. raised its holdings in Medpace by 32.4% in the 2nd quarter. BlackRock Inc. now owns 1,605,667 shares of the company’s stock valued at $69,043,000 after buying an additional 392,792 shares during the period. UBS Group AG raised its holdings in Medpace by 2,869.7% in the 1st quarter. UBS Group AG now owns 323,307 shares of the company’s stock valued at $11,286,000 after buying an additional 312,420 shares during the period. Acadian Asset Management LLC raised its holdings in Medpace by 28.2% in the 2nd quarter. Acadian Asset Management LLC now owns 1,281,533 shares of the company’s stock valued at $55,106,000 after buying an additional 282,216 shares during the period. Finally, Chartwell Investment Partners LLC purchased a new stake in Medpace in the 2nd quarter valued at about $11,190,000. Institutional investors and hedge funds own 39.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Read More: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.